- Regulatory reality
The Food and Drug Administration (FDA) regulates medical treatments in the U.S. If a stem cell therapy is not FDA-approved, it means:
- It hasn’t passed standard safety and effectiveness checks
- It may be experimental, unproven, or even unsafe
- It is often offered by private clinics operating in regulatory grey areas
UK regulators like the Charity Commission for England and Wales expect trustees to act prudently with funds—especially when health risks are involved.
- Charity law & trustee duties (UK)
Trustees must:
- Act in the best interests of the charity
- Use funds only to further the charity’s stated purposes
- Exercise reasonable care and skill
Funding an unapproved overseas therapy raises red flags:
- Is it a proper use of charitable funds?
- Is there credible medical evidence?
- Are beneficiaries being exposed to harm or false hope?
If the answer is unclear or negative, trustees could be personally accountable.
- Ethical concerns
Non-approved stem cell treatments are often linked to:
- “Medical tourism” with limited oversight
- High costs with unclear benefit
- Vulnerable patients being targeted
A charity funding such treatment risks:
- Reputational damage
- Misuse of donor funds
- Potential harm to the patient
- When might it be defensible?
There are rare edge cases where it could be considered:
- The therapy is part of a legitimate, regulated clinical trial
- There is credible peer-reviewed evidence
- No viable alternatives exist in the UK or EU
Even then, trustees would usually need:
- Independent medical advice
- Legal advice
- Full risk documentation
- Practical takeaway
For most UK charities:
Funding a non-FDA-approved stem cell therapy in the U.S. would likely be inappropriate
It could breach trustee duties unless very carefully justified
